Status: Not yet recruiting
A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC
To explore the Objective Response Rate (ORR) of Benmelstobart combined with Anlotinib and chemotherapy as first-line treatment for large-cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine carcinoma (EP-NEC)
Participants needed: 48
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Tianjin Medical University Cancer Institute and HospitalUpdated: Apr 3, 2026Locations: 1
Eligibility criteria
Histologically or cytologically confirmed metastatic LCNEC or EP-NEC (per AJCC 9... [+8]
Patients with brain metastasis and/or carcinomatous meningitis (excluding asympt... [+24]